2025 France Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 France Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Antibody Drug Conjugates (ADC) contract manufacturing in France are Catalent Inc, AbbVie Inc, Merck KGaA, and Cerbios-Pharma SA. Catalent and AbbVie offer extensive clinical to commercial ADC manufacturing services, with capabilities spanning antibody production and conjugation. Merck KGaA, headquartered in Germany but with long-standing monoclonal antibody manufacturing in France, focuses on oncology drug development including ADCs. Cerbios-Pharma, based in Switzerland near France, specializes in high-potency APIs and linker-payload conjugation critical to ADC production.
Additional notable participants include Novasep and Carbogen Amcis, which have established ADC production and conjugation sites in France, specifically in Le Mans and Riom, contributing to small-volume and cytotoxic payload synthesis and aseptic fill-finish services. These companies emphasize integrated ADC workflows combining antibody, payload, linker, conjugation, and fill-finish within GMP environments, tailored for biotech and pharmaceutical clients. The French ADC contract manufacturing market is growing, with revenues projected to exceed $516 million by 2030, driven by increasing demand for targeted cancer therapies and specialized manufacturing capabilities in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in Antibody Drug Conjugates (ADC) contract manufacturing in France are Catalent Inc, AbbVie Inc, Merck KGaA, and Cerbios-Pharma SA. Catalent and AbbVie offer extensive clinical to commercial ADC manufacturing services, with capabilities spanning antibody production and conjugation. Merck KGaA, headquartered in Germany but with long-standing monoclonal antibody manufacturing in France, focuses on oncology drug development including ADCs. Cerbios-Pharma, based in Switzerland near France, specializes in high-potency APIs and linker-payload conjugation critical to ADC production.
Additional notable participants include Novasep and Carbogen Amcis, which have established ADC production and conjugation sites in France, specifically in Le Mans and Riom, contributing to small-volume and cytotoxic payload synthesis and aseptic fill-finish services. These companies emphasize integrated ADC workflows combining antibody, payload, linker, conjugation, and fill-finish within GMP environments, tailored for biotech and pharmaceutical clients. The French ADC contract manufacturing market is growing, with revenues projected to exceed $516 million by 2030, driven by increasing demand for targeted cancer therapies and specialized manufacturing capabilities in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
